RARE Stock Collapses After Angelman Drug Fails Late-Stage Trial

Ultragenyx Pharmaceutical Inc. faces heightened pressure as key pipeline setbacks weigh on outlook, with stocks have been trading down by -46.93 percent

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading RARE

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Phase 3 Aspire trial of apazunersen (GTX-102) in Angelman syndrome failed key cognitive and MDRI endpoints, forcing a strategic rethink at RARE.
Management at Ultragenyx is planning significant expense reductions and leaning harder on its rare-disease commercial portfolio while still talking about profitability by 2027.
RARE shares plunged about 45% to $14.50 after the Phase 3 failure, wiping out a big chunk of pipeline expectations in a single session.
William Blair cut RARE to Market Perform and flagged fewer near-term catalysts after the Angelman data miss.
Evercore ISI downgraded RARE to In Line and slashed its target to $16 from $34, calling out heavy expenses, looming Crysvita competition, and reliance on first‑generation AAV gene therapies.

Live Update At 08:32:31 EDT: On Thursday, September 03, 2026 Ultragenyx Pharmaceutical Inc. stock [NASDAQ: RARE] is trending down by -46.93%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RARE just went from a slow grinder to a crashing rollercoaster. Before the Angelman news, Ultragenyx Pharmaceutical Inc. was trading in the mid‑$20s, with recent closes around $25–$26. The daily chart shows a stock stuck in a tight range for weeks, then blindsided by a gap down to the mid‑teens after the Phase 3 failure.

Fundamentally, RARE is still a classic high‑burn biotech story. Over the last quarter, Ultragenyx reported $214M in total revenue and about $180M in gross profit, showing a rich 87.8% gross margin. But the problem for traders is below the top line. Operating expenses hit roughly $255M, driven by $167M in research and $88M in G&A, leaving operating income at about -$75M and net income at -$92M.

More Breaking News

Operating cash flow was about -$97M for the quarter, with RARE ending at roughly $140M in cash and $292M including short‑term investments. The current ratio around 1.7 means near‑term liquidity is manageable, but not comfortable if the burn stays high. With a price‑to‑sales ratio near 3.5 and strongly negative margins, traders now have to judge whether the Aspire flop forces deeper cuts or fresh dilution down the road.

Why Traders Are Watching RARE After The Aspire Blowup

The new chapter for RARE starts with a single headline: Ultragenyx’s Phase 3 Aspire trial of apazunersen (GTX‑102) in Angelman syndrome failed both its main cognitive endpoint and a key MDRI measure. For a rare‑disease biotech like Ultragenyx Pharmaceutical Inc., this was not just another trial. This was one of the core pipeline assets traders were banking on for long‑term growth.

The market reaction shows how central Aspire was to the RARE story. Shares dropped about 45% to $14.50, with after‑hours trading amplifying the hit as headlines spread. When a stock loses nearly half its value in a day, that is the market repricing the future revenue stream, not just reacting to a small bump.

RARE now says it is reviewing whether to continue or terminate the program while launching significant expense reductions. Ultragenyx is telling the Street it will lean more on its growing commercial portfolio — including marketed rare‑disease drugs and potential additions like UX111 — and it is still targeting profitability by 2027. For traders, that message is a double‑edged sword. Cost cuts can extend the cash runway, but they also signal that RARE’s R&D engine just lost a major cylinder.

Analysts are lining up on the cautious side. William Blair downgraded RARE from Outperform to Market Perform, pointing to doubts around the related Aurora study of GTX‑102 and a thinner near‑term catalyst deck. Evercore ISI took an even harder stance, downgrading Ultragenyx to In Line and cutting its price target to $16 from $34. Their note highlights three big overhangs that traders need to respect: a heavy expense burden, a future loss of exclusivity for flagship product Crysvita, and dependence on first‑generation AAV gene therapies in relatively small markets.

Put together, the Aspire failure plus these downgrades shift RARE from a pipeline‑hope story to a grind‑it‑out execution story. That usually means more choppy trading, sharp bounces, and plenty of fade opportunities for disciplined day traders.

Conclusion

For active traders, RARE is now a classic “broken biotech” chart with elevated volatility and clear catalysts on the downside. The Phase 3 Angelman miss, the 45% slide to $14.50, and the twin downgrades from William Blair and Evercore ISI all reinforce the same theme: the market is questioning whether Ultragenyx Pharmaceutical Inc. can grow fast enough to justify its past spending and its old valuation.

At the same time, RARE is not a shell. Ultragenyx still posts more than $200M a quarter in revenue, sports very high gross margins, and runs a real rare‑disease commercial portfolio. Management’s plan to cut expenses and push toward 2027 profitability is a serious attempt to reset the story. If the cost actions are aggressive and the commercial base holds, the downside narrative can stabilize. If not, traders will keep pricing in dilution risk and margin pressure.

This is where process matters. Tim Sykes always reminds traders, “You’re not here to be right about the science, you’re here to trade the price action and cut losses quickly.” In the same vein, As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. RARE now offers exactly that kind of setup — huge gaps, intraday swings, and a clearly defined news catalyst. For those studying the chart, liquidity, and key levels instead of getting emotionally attached to the Ultragenyx pipeline, RARE becomes a live case study in how momentum reacts when a core biotech thesis breaks.

This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!